Physician profile
Mark A Vaughn
NPI 1477948917
$4,400.25
in general payments reported to CMS, 2019-2025
32 companies · $1,175 in 2025
The $1,175 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $306 · 2020: $470 · 2021: $583 · 2022: $623 · 2023: $861 · 2024: $382 · 2025: $1,175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,918 · Long Term Medical Supply Or Device Loan: $255 · Travel and Lodging: $244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,918.27 |
| Long Term Medical Supply Or Device Loan | $255.11 |
| Travel and Lodging | $244.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $911.87 | 2022-2025 | Nuzyra |
| Stryker Corporation | $773.70 | 2019-2025 | Prostep Mica, Gravity Synchfix, Augment Injectable |
| Arthrex, INC. | $586.46 | 2020-2025 | |
| Integra Lifesciences Corporation | $380.13 | 2019-2025 | Micromatrix, Integra, Integra Dermal Regeneration Template |
| Next Science LLC | $326.34 | 2022-2023 | Xperience, Blastx, Surgx |
| Cardiovascular Systems INC. | $211.54 | 2020 | |
| Organogenesis INC. | $152.65 | 2019-2025 | Puraply Wound Matrix, Puraply Am, Cygnus Dual |
| Kerecis Limited | $148.02 | 2021-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Horizon Therapeutics Plc | $137.71 | 2020-2022 | |
| Bioventus LLC | $115.53 | 2019-2022 | |
| Kci USA, INC. | $60.23 | 2020-2023 | V.A.C. Dermatac |
| Reel Surgical, INC. | $53.08 | 2023 | |
| Abbvie INC. | $49.48 | 2022 | |
| Smith+Nephew, INC. | $47.13 | 2019-2024 | Oasis |
| Depuy Synthes Sales INC. | $47.08 | 2023 | N/A |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Embody, INC. | $37.37 | 2021-2022 | |
| Solventum Corporation | $36.06 | 2025 | V.A.C.Ulta, V.A.C. Veraflo |
| Orthofix Medical, INC. | $32.77 | 2022 | |
| Tactile Systems Technology INC | $32.01 | 2021 | |
| Nabriva Therapeutics, Plc | $31.54 | 2021-2022 | |
| Mimedx Group, INC. | $28.12 | 2024-2025 | |
| Vertex Pharmaceuticals Incorporated | $27.06 | 2025 | |
| Sanara Medtech INC. | $24.30 | 2023 | Celleraterx |
| Globus Medical, INC. | $18.67 | 2025 | Senza |
| Axogen | $17.59 | 2021 | |
| Ermi LLC | $17.56 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $17.29 | 2023 | Seglentis |
| Merck Sharp & Dohme LLC | $17.17 | 2019 | |
| Medtronic, INC. | $16.92 | 2025 | Intellis Adaptivestim |
| Abbott Laboratories | $16.05 | 2024 | Eterna |
| Acell, INC. | $15.21 | 2019 | |
| Averitas Pharma INC. | $13.61 | 2025 | Qutenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Vaughn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.